-
1 Comment
Arix Bioscience plc is currently in a long term uptrend where the price is trading 2.0% above its 200 day moving average.
From a valuation standpoint, the stock is 60.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 517.9.
Finally, its free cash flow grew by 36.5% to $-1M since the same quarter in the previous year.
Based on the above factors, Arix Bioscience plc gets an overall score of 3/5.
Industry | Biotechnology |
---|---|
Sector | Healthcare |
ISIN | GB00BD045071 |
CurrencyCode | EUR |
Exchange | F |
Dividend Yield | 0.0% |
---|---|
Beta | 1.11 |
Target Price | None |
PE Ratio | None |
Market Cap | 153M |
Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 3HY.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024